CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Icagen Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Icagen Inc
4222 Emperor Blvd Ste 350
Phone: (919) 941-5206p:919 941-5206 DURHAM, NC  27703-8030  United States Fax: (302) 636-5454f:302 636-5454

This company ceased filing statements with the SEC on 3/9/2020.

Business Summary
Icagen, Inc., formerly XRpro Sciences, Inc., uses x-ray fluorescence technology called XRpro to deliver ion channel screening, ion channel kinetics and custom screening services to its customers. The Company's technology detects and quantitatively analyzes the x-ray signature of each element with an atomic number greater than 12. The Company provides analytical services for the United States governmental agencies. The Company's technology combines the analysis with sample processing to address a range of ion channel and various biological targets. The Company has developed molecules, such as magnetic resonance imaging (MRI) contrast agents, radiopharmaceuticals, anti-infectives and therapies for heavy metal toxicity. The Company's XRpro technology quantifies drug/protein interactions without modifying the drug, protein, or cell, or use reagents. It applies XRpro technology to assay a range of cellular processes and enzymatic functions.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Independent Non-Executive Chairman of the Board Timothy C.Tyson 68 11/24/2014 10/11/2013
President, Chief Executive Officer RichieCunningham 11/24/2014 11/24/2014
Chief Financial Officer Mark J.Korb 53 8/14/2013 8/14/2013
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Caldera Discovery, Inc.
Icagen-T, Inc.
XRpro Corp.
XRpro Sciences, Inc.

General Information
Outstanding Shares: 6,393,107 (As of 2/14/2020)
Shareholders: 285
Federal Tax Id: 200982060
Fax Number: (302) 636-5454


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023